{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:56:59Z","timestamp":1785369419720,"version":"3.55.0"},"reference-count":10,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJUI Compass"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To compare the outcomes between re\u2010induction Bacillus Calmette\u2010Gu\u00e9rin (BCG) and sequential intravesical gemcitabine\u2010docetaxel (Gem\/Doce) therapy in patients with high\u2010grade (HG) non\u2010muscle invasive bladder cancer (NMIBC) following failure of initial induction BCG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>We retrospectively identified patients who received induction BCG therapy between 2017 and 2023. Inclusion criteria were high\u2010grade NMIBC recurrence post\u2010BCG induction, with subsequent treatment by either re\u2010induction BCG or Gem\/Doce.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From 2017 to 2023, 140 patients received induction BCG, with 30 (21.4%) showing persistent HG NMIBC. Of these, five (16.7%) were treated with re\u2010induction BCG and 11 (36.7%) with Gem\/Doce. In the re\u2010induction BCG group, four patients (80%) had HGTa and one (20%) had HGT1. In the Gem\/Doce group, eight patients (73%) had HGTa, two (18%) had HGT1 and one (9%) had carcinoma in situ (CIS). Initial post\u2010treatment cystoscopy showed recurrence in one re\u2010induction BCG patient (20%) with HGT1 and CIS and in two Gem\/Doce patients (18%) with HGTa. No adverse events were reported with Gem\/Doce.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our initial experience with intravesical Gem\/Doce suggests that it is better tolerated, with fewer adverse events and comparable recurrence rates at three months, compared to re\u2010induction BCG in patients with BCG\u2010failure NMIBC.<\/jats:p><\/jats:sec>","DOI":"10.1002\/bco2.70012","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T11:07:12Z","timestamp":1743678432000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intravesical gemcitabine and docetaxel vs. re\u2010induction Bacillus Calmette Guerin as first\u2010line salvage therapy for non\u2010muscle invasive bladder cancer"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3370-3530","authenticated-orcid":false,"given":"Kylie Yen\u2010Yi","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Urology Monash Health, Casey  VIC Australia"},{"name":"School of Clinical Sciences Monash University  Clayton VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7027-2819","authenticated-orcid":false,"given":"Tran Ngoc An","family":"Huynh","sequence":"additional","affiliation":[{"name":"Department of Urology Monash Health, Casey  VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Urology Monash Health, Casey  VIC Australia"},{"name":"School of Clinical Sciences Monash University  Clayton VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincy","family":"Kuriakose","sequence":"additional","affiliation":[{"name":"Department of Urology Monash Health, Casey  VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obaidullah","family":"Fazli","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Monash Health  Clayton VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pook","sequence":"additional","affiliation":[{"name":"Department of Oncology Monash Health  Clayton VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ransley","sequence":"additional","affiliation":[{"name":"Department of Urology Monash Health, Casey  VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Downie","sequence":"additional","affiliation":[{"name":"Department of Urology Monash Health, Casey  VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Donnellan","sequence":"additional","affiliation":[{"name":"Department of Urology Monash Health, Casey  VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weranja","family":"Ranasinghe","sequence":"additional","affiliation":[{"name":"Department of Urology Monash Health, Casey  VIC Australia"},{"name":"Department of Anatomy and Developmental Biology Monash University  Clayton VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"e_1_2_5_3_1","volume-title":"European association of urology guidelines on non\u2010muscle\u2010invasive bladder cancer, TaT1 and carcinoma in situ: disease management","author":"Gontero P(C)EC","year":"2023"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.01.017"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.03.024"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000001065"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.10.030"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0849"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.04.005"},{"key":"e_1_2_5_10_1","volume-title":"Australian product information \u2010 oncotice","author":"Merck & Co","year":"2023"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.03.004"}],"container-title":["BJUI Compass"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bco2.70012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:48:38Z","timestamp":1759938518000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1002\/bco2.70012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/bco2.70012"],"URL":"https:\/\/doi.org\/10.1002\/bco2.70012","archive":["Portico"],"relation":{},"ISSN":["2688-4526","2688-4526"],"issn-type":[{"value":"2688-4526","type":"print"},{"value":"2688-4526","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2025-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70012"}}